Exelixis Stock (NASDAQ:EXEL)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$22.76

52W Range

$18.64 - $24.34

50D Avg

$21.75

200D Avg

$22.06

Market Cap

$6.56B

Avg Vol (3M)

$1.84M

Beta

0.54

Div Yield

-

EXEL Company Profile


Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

1,310

IPO Date

Apr 17, 2000

Website

EXEL Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Service$22.69M--
License$178.63M--
Product$1.63B$1.40B$1.08B
Product, Gross$2.27B$1.95B$1.45B
Product, Sales Discounts And Allowances$-643.65M$-549.93M$-375.66M
Collaboration$201.33M$209.82M$357.71M

Fiscal year ends in Dec 23 | Currency in USD

EXEL Financial Summary


Dec 23Dec 22Dec 21
Revenue$1.83B$1.61B$1.43B
Operating Income$170.88M$201.48M$286.67M
Net Income$207.76M$182.28M$231.06M
EBITDA$196.60M$201.48M$286.67M
Basic EPS$0.65$0.57$0.73
Diluted EPS$0.65$0.56$0.72

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q1 24Apr 30, 24 | 9:27 PM
Q4 23Feb 06, 24 | 10:13 PM
Q3 23Nov 01, 23 | 9:43 PM

Peer Comparison


TickerCompany
HALOHalozyme Therapeutics, Inc.
PTCTPTC Therapeutics, Inc.
TGTXTG Therapeutics, Inc.
BMRNBioMarin Pharmaceutical Inc.
VKTXViking Therapeutics, Inc.
BTAIBioXcel Therapeutics, Inc.
XFORX4 Pharmaceuticals, Inc.
ALNYAlnylam Pharmaceuticals, Inc.
PDSBPDS Biotechnology Corporation
MDGLMadrigal Pharmaceuticals, Inc.
KODKodiak Sciences Inc.
SRPTSarepta Therapeutics, Inc.
KRYSKrystal Biotech, Inc.